AN OPPORTUNITY TO HOLD BIG PHARMA ACCOUNTABLE
The U.S. House of Representatives Committee on Oversight and Reform is scheduled to hold two days of hearings with Big Pharma executives on September 30 and October 1. Executives for brand name drug giants including Bristol Myers Squibb/Celgene, Amgen and Novartis are slated to testify. Lawmakers must use this opportunity to press these executives on their companies’ egregious pricing practices and anti-competitive tactics to reignite momentum for action to hold Big Pharma accountable.